Insmed IncorporatedInsmed IncorporatedInsmed Incorporated

Insmed Incorporated

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪34.49 B‬USD
−5.5USD
‪−913.77 M‬USD
‪363.71 M‬USD
‪207.27 M‬
Beta (1Y)
0.90
Employees (FY)
‪1.27 K‬
Change (1Y)
+359 +39.36%
Revenue / Employee (1Y)
‪286.16 K‬USD
Net income / Employee (1Y)
‪−718.94 K‬USD

About Insmed Incorporated


CEO
William H. Lewis
Website
Headquarters
Bridgewater
Founded
1988
ISIN
US4576693075
FIGI
BBG00JVRNS34
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Check out other big names from the same industry as 0JAV.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
VTI
Vanguard Total Stock Market ETF
Weight
0.05%
Market value
‪960.85 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.44%
Market value
‪721.49 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
1.01%
Market value
‪403.72 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.38%
Market value
‪325.71 M‬
USD
IBB
iShares Biotechnology ETF
Weight
3.20%
Market value
‪211.39 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
0.95%
Market value
‪194.85 M‬
USD
XBI
SPDR S&P BIOTECH ETF
Weight
1.89%
Market value
‪131.15 M‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
0.09%
Market value
‪112.20 M‬
USD
IWR
iShares Russell Midcap ETF
Weight
0.25%
Market value
‪110.97 M‬
USD
JGRO
JPMorgan Active Growth ETF
Weight
1.26%
Market value
‪96.98 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.46%
Market value
‪81.40 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 0JAV is 165.5 USD — it has increased by 1.15% in the past 24 hours. Watch Insmed Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Insmed Incorporated stocks are traded under the ticker 0JAV.
0JAV stock has fallen by −1.58% compared to the previous week, the month change is a 13.27% rise, over the last year Insmed Incorporated has showed a 122.03% increase.
We've gathered analysts' opinions on Insmed Incorporated future price: according to them, 0JAV price has a max estimate of 240.00 USD and a min estimate of 139.00 USD. Watch 0JAV chart and read a more detailed Insmed Incorporated stock forecast: see what analysts think of Insmed Incorporated and suggest that you do with its stocks.
0JAV reached its all-time high on Oct 10, 2025 with the price of 168.0 USD, and its all-time low was 16.5 USD and was reached on Mar 27, 2023. View more price dynamics on 0JAV chart.
See other stocks reaching their highest and lowest prices.
0JAV stock is 1.80% volatile and has beta coefficient of 0.90. Track Insmed Incorporated stock price on the chart and check out the list of the most volatile stocks — is Insmed Incorporated there?
Today Insmed Incorporated has the market capitalization of ‪35.04 B‬, it has increased by 0.53% over the last week.
Yes, you can track Insmed Incorporated financials in yearly and quarterly reports right on TradingView.
Insmed Incorporated is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
0JAV earnings for the last quarter are −1.70 USD per share, whereas the estimation was −1.30 USD resulting in a −30.84% surprise. The estimated earnings for the next quarter are −1.34 USD per share. See more details about Insmed Incorporated earnings.
Insmed Incorporated revenue for the last quarter amounts to ‪107.42 M‬ USD, despite the estimated figure of ‪104.13 M‬ USD. In the next quarter, revenue is expected to reach ‪115.05 M‬ USD.
0JAV net income for the last quarter is ‪−321.69 M‬ USD, while the quarter before that showed ‪−256.58 M‬ USD of net income which accounts for −25.37% change. Track more Insmed Incorporated financial stats to get the full picture.
No, 0JAV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 18, 2025, the company has ‪1.27 K‬ employees. See our rating of the largest employees — is Insmed Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insmed Incorporated EBITDA is ‪−915.32 M‬ USD, and current EBITDA margin is −213.24%. See more stats in Insmed Incorporated financial statements.
Like other stocks, 0JAV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insmed Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Insmed Incorporated technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Insmed Incorporated stock shows the strong buy signal. See more of Insmed Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.